Abstract-For the investigation of the minimal structural requirements for cytokine induction, Staphylococcus aureus lipoteichoic acid derivatives with two, three, four, and five glycerophosphate backbone moieties, carrying each a D D-alanyl residue, were needed. Based on two different glycerophosphate building blocks and 6b-O-phosphitylated gentiobiosyl diacylglycerol the desired target molecules (compounds 1-4) could be readily obtained and provided for biological studies.
Introduction
During infection, the recognition of conserved bacterial structures called pathogen-associated molecular patterns occurs via receptor recognition on immune cells and leads to the activation of the innate immune system resulting in the release of a variety of cytokines. Lipopolysaccharides (LPS) have been known as the most important conserved bacterial structures of Gram-negative bacteria inducing cytokine release for more than 50 years. 1 Immune recognition takes place by the binding of LPS to the toll-like receptor 4 (TLR4) involving also other co-factors. [2] [3] [4] The immunostimulatory component of Gram-positive bacteria was not clear for a long time, although a structural counterpart of LPS called lipoteichoic acid (LTA) was found in the bacterial membrane; this LTA is also an amphiphilic molecule with a lipid anchor and a generally negatively charged glycerophosphate backbone. An improved preparation procedure applied to the isolation of LTA from Staphylococcus aureus led to biologically active LTA, [5] [6] [7] whose structure could be assigned by NMR and MS data. 5, 8 The receptor for LTA recognition is TLR2 9 accompanied by the co-factors TLR6, 7 CD14, 10, 11 and CD36. 12 Modifications of the LTA structure gave information on the prerequisites for the induction of cytokine release. For instance, a complete deacylation led to less active material and selective removal of the D D-alanyl residues from the glycerophosphate backbone which strongly reduced the immunostimulatory potency. 8 This result indicated that the lipid anchor and also the D D-alanyl residues are essential for the immunostimulatory potency. The chemical synthesis of a truncated LTA, based on the native LTA structure of S. aureus, confirmed these results. 13, 14 To determine the key components for immune cell activation, several LTA derivatives were synthesized starting from a molecule with two lipid anchors (=two gentiobiosyl-diacylglycerol anchors) and a backbone with six glycerophosphate units substituted by four D D-alanine residues and one N-acetyl-D D-glucosamine residue which was more potent than natural LTA. 15 Neither the absence of the gentiobiose residue nor the loss of N-acetyl-D D-glucosamine altered the ability of LTA with one lipid anchor to induce cytokine release; only replacement of D D-alanine by L L-alanine blunted the cytokine-inducing potency. 16, 17 These results approximated the crucial pattern required for the immune recognition of LTA and prompted us to synthesize further LTA derivatives with a reduced structure down to the synthetic anchor, namely gentiobiosyl-diacylglycerol, in order to determine the minimal structural requirements for cytokine induction. For these studies compounds 1-4 (Scheme 1) were needed. The synthesis of these compounds is described in this paper.
Results and discussion
The retrosynthesis of compounds 1-4 is shown in Scheme 1. Disintegrations -lead to building blocks 5-7 and to N-benzyloxy-carbonyl (Z)-protected D D-alanine. These building blocks consider the presence of gentiobiosyl diacylglycerol, O-(D D-alanyl)-glycerol, and 2-Ononsubstituted glycerol residues, respectively, and their sequence specific linkage via mixed phosphorous diester bonds. Also the most important aspect, the hydrolytic lability of the D D-alanyl residues, which are readily cleaved at pH 8.5, 13 is taken into account: as temporary protecting group for building block 6, the p-methoxylbenzyl (PMB) group is chosen which can be selectively cleaved after completion of the backbone synthesis. Following the attachment of D D-alanyl residues with Z-protected D D-alanine and then a complete O-debenzylation will provide the target molecules.
The synthesis of the previously designed building blocks 5-7 and also the sequence specific synthesis of oligomers 8-10 (Scheme 2) has been already reported. 14 residues (!24), and final deprotection afforded target molecule 4. In summary, the previously designed building blocks for the synthesis of S. aureus LTA proved to be highly versatile, thus permitting the preparation of variously modified LTAs. This cassette containing about six building blocks laid the basis for successful structureactivity relationship studies. 21 The biological studies with compounds 1-4 and some previously prepared S. aureus LTA modifications revealed the following: 21 The synthetic lipid anchor alone was not sufficient to induce cytokine release, however, the addition of three unsubstituted glycerophosphate backbone units exhibits this activity. The TLR2-dependent activation was amplified about 10-fold by substitution with at least two D D-alanyl residues (compound 2)-but not by L L-alanyl residues. Hence, with compounds 1-4 the minimal structural requirement for LTA pattern recognition by immune cells could be defined.
Experimental

General methods
Solvents were dried according to standard procedures. NMR spectroscopic measurements were performed at 22°C with a Bruker DRX600 and Bruker AC250 
A mixture of the glycerol moiety 10 17 (1.63 g, 0.94 mmol) and phosphite amide 6 17 (0.78 g, 1.2 equiv) was co-evaporated with dry CH 2 Cl 2 and dried for 1 h in high vacuum. The reaction mixture was dissolved in CH 2 Cl 2 (50 mL), and tetrazole was added (132 mg, 1.88 mmol, dried previously 1 h in a high vacuum). The reaction mixture was stirred for 1.5 h at rt (TLC petroleum ether/EtOAc 2:1, 1% NEt 3 , R f 0.74) and t-BuOOH (1.5 mL) was added. After 20 min, the reaction mixture was diluted with CH 2 Cl 2 and washed with satd NaHCO 3 solution, the organic phase was dried over MgSO 4 
Compound 8 17 (250 mg, 0.250 mmol) and phosphite amide 7
15 (403 mg, 1.3 equiv) were co-evaporated each with 10 mL of dry CH 2 Cl 2 and dried 1h in high vacuum. Phosphite amide 7 was dissolved in 10 mL of dry CH 2 Cl 2 and was added, under argon atmosphere, to compound 8; tetrazole (36 mg, 2 equiv, dried previously 1 h in high vacuum) was also added. The reaction mixture was stirred at rt under argon atmosphere. After 70 min were added dropwise 0.7 mL of t-BuOOH, and the reaction mixture was stirred for another 35 min. CH 2 Cl 2 was added to dilute and the mixture was washed with satd NaHCO 3 solution, the organic phase was dried over MgSO 4 and the solvent removed under diminished pressure. Purification by flash chromatography (petroleum ether/EtOAc 2:1) gave compound 13 (464 mg, 73%) as a colorless syrup, which was stored at À20°C. TLC (petroleum ether/ 
Compound 13 (450mg, 0.178 mmol) was dissolved in acetonitrile/toluene/water (60:3:4, 30 mL) and cooled to À10°C. Ce(NH 4 ) 2 (NO 3 ) 6 (0.776 g, 8 equiv) was added portionwise and the reaction mixture stirred for 20 min at À10°C, the cooling bath was removed and the reaction mixture was stirred for another 30-40 min (TLC-monitoring). After this time the reaction mixture was diluted with EtOAc and washed with satd NaHCO 3 solution, the organic phase was dried over MgSO 4 and was evaporated under diminished pressure. A fast purification in silica gel (2.5:1 toluene-acetone) yielded compound 14 (294 mg, 72%) as a colorless syrup, which was stored at À20°C. 
Compound 16 was synthesized following the procedure described for compound 13. 
(2,3-
Compound 17 was synthesized following the same procedure as described for compound 14 
Compound 18 was synthesized following the same procedure as described for compound 15 
Compound 19 was synthesized following the procedure described for compound 13. 23 (m, 1H, 1a-H), 4.27 (m, 1H, 6b-H), 4.43 (m, 1H, 1b-H 
Compound 21 was synthesized following the same procedure as described for compound 15. 
Compound 22 was synthesized following the procedure described for compound 13. 
Compound 24 was synthesized following the same procedure as described for compound 15. 1C, C-3 0 ), 65.0 (10 C, C-1, C-3, C-4, C-6, C-7, C-9, C-10, C-12, C-13, C-15), 66.5 (1C, C-6b 0 -H). 13 Compound 2 was synthesized following the same procedure as described for compound 1. 
